GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MEI Pharma Inc (NAS:MEIP) » Definitions » Net Debt Paydown Yield %

MEIP (MEI Pharma) Net Debt Paydown Yield % : 7.06% (As of Apr. 12, 2025)


View and export this data going back to 2003. Start your Free Trial

What is MEI Pharma Net Debt Paydown Yield %?

Net Debt Paydown Yield % is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. It is a measure of a company's willingness and ability to reduce its debt. As of today, MEI Pharma's Net Debt Paydown Yield % was 7.06%.


MEI Pharma Net Debt Paydown Yield % Historical Data

The historical data trend for MEI Pharma's Net Debt Paydown Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MEI Pharma Net Debt Paydown Yield % Chart

MEI Pharma Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Net Debt Paydown Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - -0.43 -9.83 6.10

MEI Pharma Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Net Debt Paydown Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.23 0.88 6.10 5.45 5.37

Competitive Comparison of MEI Pharma's Net Debt Paydown Yield %

For the Biotechnology subindustry, MEI Pharma's Net Debt Paydown Yield %, along with its competitors' market caps and Net Debt Paydown Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MEI Pharma's Net Debt Paydown Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MEI Pharma's Net Debt Paydown Yield % distribution charts can be found below:

* The bar in red indicates where MEI Pharma's Net Debt Paydown Yield % falls into.


;
;

MEI Pharma Net Debt Paydown Yield % Calculation

MEI Pharma's Net Debt Paydown Yield % for the quarter that ended in Dec. 2024 is calculated as:

Net Debt Paydown Yield %
=( TTM Average Debt   (1-Year Ago))-TTM Average Debt )/Market Cap
=( 12.55-11.67 )/16.39098
=5.37 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Net Debt Paydown Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.


MEI Pharma  (NAS:MEIP) Net Debt Paydown Yield % Explanation

Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced. In other words, it is a measure of the willingness and ability of a firm's management to pay down debt. Companies that have high debt paydown yields indicate that they are more aggressive with paying down debt.

In the calculation of Net Debt Paydown Yield %, we use the reductions of TTM average total debt one-year-ago and TTM average total debt at present, divided by its Market Cap.

We calculating the TTM average debt by adding up the total debt, calculated by the sum of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation, in the trailing twelve months(TTM) divided by the counts of the total debt, accoring to the company's report frequency.


MEI Pharma Net Debt Paydown Yield % Related Terms

Thank you for viewing the detailed overview of MEI Pharma's Net Debt Paydown Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


MEI Pharma Business Description

Traded in Other Exchanges
Address
9920 Pacific Heights Blvd, Suite 150, San Diego, CA, USA, 92121
MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.
Executives
Taheer Datoo director 181 BAY STREET, SUITE 4200, TORONTO A6 M5J 2T3
James P Flynn director 41 HARRIS CT, DANVILLE CA 94526
Sujay Kango director 1028 CHAMBERS COURT, BRIDGEWATER NJ 08807
Richard G Ghalie officer: Chief Medical Officer C/O FAVRILLE, INC, 10445 PACIFIC CENTER COURT, SAN DIEGO CA 92121
Bruce Ross Winson 10 percent owner 5950 BERKSHIRE LANE, SUITE 510, DALLAS TX 75225
Anson Funds Management Lp 10 percent owner 16000 DALLAS PARKWAY, SUITE 800, DALLAS TX 75248
Anson Management Gp Llc 10 percent owner 16000 DALLAS PARKWAY, SUITE 800, DALLAS TX 75248
Anson Advisors Inc. 10 percent owner 155 UNIVERSITY AVENUE, SUITE 207, TORONTO A6 M5H 3B7
Funicular Funds, Lp 10 percent owner 2261 MARKET STREET, #4307, SAN FRANCISCO CA 94114
Amin Nathoo 10 percent owner 155 UNIVERSITY AVENUE, SUITE 207, TORONTO Z4 M5H 3B7
Moez Kassam 10 percent owner 111 PETER STREET, SUITE 904, TORONTO A6 M5V2H1
Justin J. File officer: CFO and Corporate Secretary C/O EVOFEM BIOSCIENCES, INC., 12400 HIGH BLUFF DRIVE, SUITE 600, SAN DIEGO CA 92130
Jacob Ma-weaver 10 percent owner 2261 MARKET STREET, #4307, SAN FRANCISCO CA 94114
Cable Car Capital Llc 10 percent owner 2261 MARKET STREET #4307, SAN FRANCISCO CA 94114
Baltic Charles V. Iii director C/O MARSHALL EDWARDS, INC., 11975 EL CAMINO REAL, SUITE 101, SAN DIEGO CA 92130